Others have also shown that tumor-derived TLR2 ligands (like versican) induced DC dysfunction in the B16 TME, and in this context, lack of TLR2 or versican improved DC activation and subsequently T cell responses against the (26). The gene discussed is TLR2; the disease is neoplasm.